All In Biotech

Drug Trial Radar · NCT05949684

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

402

Actual

Start

Oct 24, 2023

Primary completion

Mar 24, 2028

Study completion May 30, 2031

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).

Conditions

  • Myelodysplastic Syndromes

Interventions

  • LuspaterceptBiological

    Specified dose on specified days

  • Epoetin AlfaBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with lower-risk non-transfusion dependent myelodysplastic syndromes (NTD-MDS) who converted to Transfusion Dependence (TD) during any continuous 16-week interval within the 96-week treatment periodTime frame: Up to Week 96
  2. Number of participants with an increase from baseline in mean Hb values of ≥ 1.5 grams/deciliter (g/dL) in any continuous 16-week interval within the 48 week Treatment Period in the absence of transfusionTime frame: Up to Week 48

Locations

144 sites in 19 countries. Site status is shown where the registry gives one.

  • Local Institution - 0070

    Clovis, California

  • Local Institution - 0179

    Fountain Valley, California

  • Local Institution - 0211

    Los Alamitos, California

  • Local Institution - 0258

    Los Angeles, California

  • Local Institution - 0247

    Orange, California

  • Local Institution - 0209

    Oxnard, California

  • Local Institution - 0183

    Walnut Creek, California

  • Local Institution - 0227

    Hartford, Connecticut

  • Local Institution - 0173

    New Haven, Connecticut

  • Halifax Health Medical Center

    Daytona Beach, Florida

  • Local Institution - 0202

    Fort Myers, Florida

  • Local Institution - 0180

    Jacksonville, Florida

  • Local Institution - 0224

    Margate, Florida

  • Local Institution - 0163

    Plantation, Florida

  • Local Institution - 0201

    St. Petersburg, Florida

  • Local Institution - 0238

    Tamarac, Florida

  • Local Institution - 0106

    Tampa, Florida

  • Local Institution - 0240

    Honolulu, Hawaii

  • Local Institution - 0272

    Chicago, Illinois

  • Local Institution - 0184

    Skokie, Illinois

  • Local Institution - 0270

    Dyer, Indiana

  • Local Institution - 0191

    Baton Rouge, Louisiana

  • Local Institution - 0044

    Covington, Louisiana

  • Local Institution - 0007

    Bethesda, Maryland

  • Local Institution - 0222

    Saint Louis Park, Minnesota

  • Local Institution - 0128

    Hattiesburg, Mississippi

  • Local Institution - 0212

    Hackensack, New Jersey

  • Local Institution - 0206

    Columbus, Ohio

  • Local Institution - 0174

    Knoxville, Tennessee

  • Local Institution - 0228

    Houston, Texas

  • Local Institution - 0236

    Richmond, Virginia

  • Local Institution - 0229

    Roanoke, Virginia

  • Local Institution - 0203

    Kennewick, Washington

  • Local Institution - 0010

    Buenos Aires, Argentina

  • Local Institution - 0009

    Buenos Aires, Argentina

  • Local Institution - 0012

    Buenos Aires, Argentina

  • Local Institution - 0071

    Blacktown, New South Wales, Australia

  • Local Institution - 0113

    Camperdown, New South Wales, Australia

  • Local Institution - 0254

    Coffs Harbour, New South Wales, Australia

  • Local Institution - 0246

    Gold Coast, Queensland, Australia

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.